Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: NCT03640312 Eligibility Criteria

Raw xml | Download

<Group xmlns="http://hl7.org/fhir">
  <id value="367881"/>
  <meta>
    <versionId value="27"/>
    <lastUpdated value="2026-04-01T14:32:24.925Z"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Group 367881</b></p><a name="367881"> </a><a name="hc367881"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 27; Last updated: 2026-04-01 14:32:24+0000</p></div><p><b>ArtifactPublicationStatus</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}">Active</span></p><p><b>Artifact Author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><p><b>CiteAs</b>: </p><div><p>NCT03640312 Eligibility Criteria [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367881. Revised 2026-04-01. Available at: https://fevir.net/resources/Group/367881. Computable resource at: https://fevir.net/resources/Group/367881#json.</p>
</div><p><b>url</b>: <a href="https://fevir.net/resources/Group/367881">https://fevir.net/resources/Group/367881</a></p><p><b>identifier</b>: FEvIR Object Identifier/367881, FEvIR Linking Identifier/NCT03640312 Eligibility Criteria</p><p><b>name</b>: NCT03640312_Eligibility_Criteria</p><p><b>title</b>: NCT03640312 Eligibility Criteria</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p>Inclusion Criteria:</p>
<ul>
<li>Adults (≥18 years)</li>
<li>Spanish or English speaker.</li>
<li>Previous documentation within the past 24 months of hypertension or high blood pressure (SBP 130-179 mmHg or DBP 80-109 mmHg) from general practitioner, pharmacist or health care professional (e.g., medical assistant, physician or nurse).</li>
<li>Either: 1) Untreated (automated) clinic SBP 140-179 or DBP 90-109 mmHg in the last 12 weeks, OR 2) Monotherapy with clinic SBP 130-159 or DBP 85-99 mmHg in the last 12 weeks.</li>
<li>Either: 1) Treatment naïve, OR 2) Currently not on treatment (not take in last 4 weeks), OR 3) Currently taking 1 BP lowering drug (ACE, ARB, CCB, thiazide- or thiazide-like diuretic, BB, MRA, alpha blocker) at any dose.</li>
<li>Research grade blood pressure measurement (baseline mean) SBP&gt;= 115 mmHg and DBP &gt;= 60 mmHg
Exclusion Criteria:</li>
<li>Known contraindication to candesartan, amlodipine, indapamide or bisoprolol.</li>
<li>Previous diagnosis of coronary artery disease, stroke, or heart failure.</li>
<li>Presence of significant proteinuria (based on 3+ proteinuria via spot urinalysis or &gt;300mg/dL of proteinuria based on random urinary albumin-to-creatinine ratio testing of 300 mg/g)</li>
<li>Evidence of secondary cause of hypertension e.g., renal artery stenosis; significant renal impairment (eGFR &lt;50 ml/min/1.73 m2), raised serum potassium (above lab normal limit of 5.5 mEq/L).</li>
<li>Women who are pregnant, breast feeding or of childbearing potential and are not using and do not plan to continue using medically acceptable form of contraception throughout the study (pharmacological or barrier methods).</li>
<li>Concomitant illness, physical impairment or mental condition which in the opinion of the study team / primary care physician could interfere with the conduct of the study including outcome assessments.</li>
<li>Participation in a concurrent interventional medical investigation or pharmacologic clinical trial. Patients in observational, natural history or epidemiological studies not involving an intervention are eligible.</li>
<li>Participant's responsible primary care or other responsible physician believes it is not appropriate for participant to switch current monotherapy.</li>
<li>Inability or unwillingness to provide written informed consent.</li>
<li>Unable to complete study procedures.</li>
</ul>
</div><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><p><b>membership</b>: Conceptual</p><p><b>combinationMethod</b>: All of</p><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Adults (≥18 years)</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Spanish or English speaker.</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Previous documentation within the past 24 months of hypertension or high blood pressure (SBP 130-179 mmHg or DBP 80-109 mmHg) from general practitioner, pharmacist or health care professional (e.g., medical assistant, physician or nurse).</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Either: 1) Untreated (automated) clinic SBP 140-179 or DBP 90-109 mmHg in the last 12 weeks, OR 2) Monotherapy with clinic SBP 130-159 or DBP 85-99 mmHg in the last 12 weeks.</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Either: 1) Treatment naïve, OR 2) Currently not on treatment (not take in last 4 weeks), OR 3) Currently taking 1 BP lowering drug (ACE, ARB, CCB, thiazide- or thiazide-like diuretic, BB, MRA, alpha blocker) at any dose.</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Research grade blood pressure measurement (baseline mean) SBP\&gt;= 115 mmHg and DBP \&gt;= 60 mmHg</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Known contraindication to candesartan, amlodipine, indapamide or bisoprolol.</span></p><p><b>exclude</b>: true</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Previous diagnosis of coronary artery disease, stroke, or heart failure.</span></p><p><b>exclude</b>: true</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Presence of significant proteinuria (based on 3+ proteinuria via spot urinalysis or \&gt;300mg/dL of proteinuria based on random urinary albumin-to-creatinine ratio testing of 300 mg/g)</span></p><p><b>exclude</b>: true</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Evidence of secondary cause of hypertension e.g., renal artery stenosis; significant renal impairment (eGFR \&lt;50 ml/min/1.73 m2), raised serum potassium (above lab normal limit of 5.5 mEq/L).</span></p><p><b>exclude</b>: true</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Women who are pregnant, breast feeding or of childbearing potential and are not using and do not plan to continue using medically acceptable form of contraception throughout the study (pharmacological or barrier methods).</span></p><p><b>exclude</b>: true</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Concomitant illness, physical impairment or mental condition which in the opinion of the study team / primary care physician could interfere with the conduct of the study including outcome assessments.</span></p><p><b>exclude</b>: true</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Participation in a concurrent interventional medical investigation or pharmacologic clinical trial. Patients in observational, natural history or epidemiological studies not involving an intervention are eligible.</span></p><p><b>exclude</b>: true</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Participant's responsible primary care or other responsible physician believes it is not appropriate for participant to switch current monotherapy.</span></p><p><b>exclude</b>: true</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Inability or unwillingness to provide written informed consent.</span></p><p><b>exclude</b>: true</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Unable to complete study procedures.</span></p><p><b>exclude</b>: true</p></blockquote></div>
  </text>
  <extension
             url="http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status">
    <valueCodeableConcept>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/cited-artifact-status-type"/>
        <code value="active"/>
        <display value="Active"/>
      </coding>
    </valueCodeableConcept>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <name
            value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as">
    <valueMarkdown
                   value="NCT03640312 Eligibility Criteria [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367881. Revised 2026-04-01. Available at: https://fevir.net/resources/Group/367881. Computable resource at: https://fevir.net/resources/Group/367881#json."/>
  </extension>
  <url value="https://fevir.net/resources/Group/367881"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net/FOI"/>
    <value value="367881"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <type>
      <text value="FEvIR Linking Identifier"/>
    </type>
    <system value="https://fevir.net/FLI"/>
    <value value="NCT03640312 Eligibility Criteria"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <name value="NCT03640312_Eligibility_Criteria"/>
  <title value="NCT03640312 Eligibility Criteria"/>
  <status value="active"/>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <description
               value="Inclusion Criteria:
* Adults (≥18 years)
* Spanish or English speaker.
* Previous documentation within the past 24 months of hypertension or high blood pressure (SBP 130-179 mmHg or DBP 80-109 mmHg) from general practitioner, pharmacist or health care professional (e.g., medical assistant, physician or nurse).
* Either: 1) Untreated (automated) clinic SBP 140-179 or DBP 90-109 mmHg in the last 12 weeks, OR 2) Monotherapy with clinic SBP 130-159 or DBP 85-99 mmHg in the last 12 weeks.
* Either: 1) Treatment naïve, OR 2) Currently not on treatment (not take in last 4 weeks), OR 3) Currently taking 1 BP lowering drug (ACE, ARB, CCB, thiazide- or thiazide-like diuretic, BB, MRA, alpha blocker) at any dose.
* Research grade blood pressure measurement (baseline mean) SBP\&gt;= 115 mmHg and DBP \&gt;= 60 mmHg
Exclusion Criteria:
* Known contraindication to candesartan, amlodipine, indapamide or bisoprolol.
* Previous diagnosis of coronary artery disease, stroke, or heart failure.
* Presence of significant proteinuria (based on 3+ proteinuria via spot urinalysis or \&gt;300mg/dL of proteinuria based on random urinary albumin-to-creatinine ratio testing of 300 mg/g)
* Evidence of secondary cause of hypertension e.g., renal artery stenosis; significant renal impairment (eGFR \&lt;50 ml/min/1.73 m2), raised serum potassium (above lab normal limit of 5.5 mEq/L).
* Women who are pregnant, breast feeding or of childbearing potential and are not using and do not plan to continue using medically acceptable form of contraception throughout the study (pharmacological or barrier methods).
* Concomitant illness, physical impairment or mental condition which in the opinion of the study team / primary care physician could interfere with the conduct of the study including outcome assessments.
* Participation in a concurrent interventional medical investigation or pharmacologic clinical trial. Patients in observational, natural history or epidemiological studies not involving an intervention are eligible.
* Participant's responsible primary care or other responsible physician believes it is not appropriate for participant to switch current monotherapy.
* Inability or unwillingness to provide written informed consent.
* Unable to complete study procedures."/>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <membership value="conceptual"/>
  <combinationMethod value="all-of"/>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text value="Adults (≥18 years)"/>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text value="Spanish or English speaker."/>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Previous documentation within the past 24 months of hypertension or high blood pressure (SBP 130-179 mmHg or DBP 80-109 mmHg) from general practitioner, pharmacist or health care professional (e.g., medical assistant, physician or nurse)."/>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Either: 1) Untreated (automated) clinic SBP 140-179 or DBP 90-109 mmHg in the last 12 weeks, OR 2) Monotherapy with clinic SBP 130-159 or DBP 85-99 mmHg in the last 12 weeks."/>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Either: 1) Treatment naïve, OR 2) Currently not on treatment (not take in last 4 weeks), OR 3) Currently taking 1 BP lowering drug (ACE, ARB, CCB, thiazide- or thiazide-like diuretic, BB, MRA, alpha blocker) at any dose."/>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Research grade blood pressure measurement (baseline mean) SBP\&gt;= 115 mmHg and DBP \&gt;= 60 mmHg"/>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Known contraindication to candesartan, amlodipine, indapamide or bisoprolol."/>
    </valueCodeableConcept>
    <exclude value="true"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Previous diagnosis of coronary artery disease, stroke, or heart failure."/>
    </valueCodeableConcept>
    <exclude value="true"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Presence of significant proteinuria (based on 3+ proteinuria via spot urinalysis or \&gt;300mg/dL of proteinuria based on random urinary albumin-to-creatinine ratio testing of 300 mg/g)"/>
    </valueCodeableConcept>
    <exclude value="true"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Evidence of secondary cause of hypertension e.g., renal artery stenosis; significant renal impairment (eGFR \&lt;50 ml/min/1.73 m2), raised serum potassium (above lab normal limit of 5.5 mEq/L)."/>
    </valueCodeableConcept>
    <exclude value="true"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Women who are pregnant, breast feeding or of childbearing potential and are not using and do not plan to continue using medically acceptable form of contraception throughout the study (pharmacological or barrier methods)."/>
    </valueCodeableConcept>
    <exclude value="true"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Concomitant illness, physical impairment or mental condition which in the opinion of the study team / primary care physician could interfere with the conduct of the study including outcome assessments."/>
    </valueCodeableConcept>
    <exclude value="true"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Participation in a concurrent interventional medical investigation or pharmacologic clinical trial. Patients in observational, natural history or epidemiological studies not involving an intervention are eligible."/>
    </valueCodeableConcept>
    <exclude value="true"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Participant's responsible primary care or other responsible physician believes it is not appropriate for participant to switch current monotherapy."/>
    </valueCodeableConcept>
    <exclude value="true"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Inability or unwillingness to provide written informed consent."/>
    </valueCodeableConcept>
    <exclude value="true"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text value="Unable to complete study procedures."/>
    </valueCodeableConcept>
    <exclude value="true"/>
  </characteristic>
</Group>